Murphy G P, Maguire R T, Rogers B, Partin A W, Nelp W B, Troychak M J, Ragde H, Kenny G M, Barren R J, Bowes V A, Gregorakis A K, Holmes E H, Boynton A L
Pacific Northwest Cancer Foundation/Northwest Hospital, Seattle, WA 98125-7001, USA.
Prostate. 1997 Dec 1;33(4):281-5. doi: 10.1002/(sici)1097-0045(19971201)33:4<281::aid-pros9>3.0.co;2-k.
Stored serum from clinical trial cases undergoing ProstaScint (CYT-356) scanning were available for Prostate Specific Membrane Antigen (PSMA) assay. Prostate Specific Antigen (PSA) levels had already been determined. This provided an opportunity to see what correlations existed between the serum markers and the ProstaScint scan. A group of patients had the studies preprostatectomy, whereas another group had the studies postprostatectomy.
The scan results, serum PSA, serum PSMA, and clinical data were separately analyzed. PSMA serum levels were determined by Western blot.
Preoperatively, radical prostatectomy patients showed a correlation between serum PSA or PSMA levels and the ProstaScint scan in the total group (n = 86), or in an untreated group (n = 38). Preoperatively, PSMA correlated with the pathological stage, whereas PSA correlated with the scan. Postoperatively, only PSMA serum levels correlated with the scan in an untreated group (n = 40).
Preoperatively or postoperatively, Western blot PSMA serum levels predict the stage of disease or local, regional, or distant metastases, as shown by ProstaScint scan. Both the scan and the serum tests provide prognostic information and evaluate the extent of disease to a more significant degree than previously possible.
接受ProstaScint（CYT - 356）扫描的临床试验病例所储存的血清可用于前列腺特异性膜抗原（PSMA）检测。前列腺特异性抗原（PSA）水平已经测定。这提供了一个机会来观察血清标志物与ProstaScint扫描之间存在何种相关性。一组患者在前列腺切除术前进行了这些研究，而另一组患者在前列腺切除术后进行了研究。
分别分析扫描结果、血清PSA、血清PSMA和临床数据。PSMA血清水平通过蛋白质印迹法测定。
术前，在整个组（n = 86）或未治疗组（n = 38）中，根治性前列腺切除术患者的血清PSA或PSMA水平与ProstaScint扫描之间存在相关性。术前，PSMA与病理分期相关，而PSA与扫描相关。术后，仅在未治疗组（n = 40）中，PSMA血清水平与扫描相关。
如ProstaScint扫描所示，术前或术后，蛋白质印迹法测定的PSMA血清水平可预测疾病分期或局部、区域或远处转移。扫描和血清检测均提供预后信息，并比以前更显著地评估疾病范围。
